维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

10篇 您的检索式：作者名="Hira B"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin显示文摘	Malhowski A.J Hira H Bashiruddin S Warburton R Goto J Robert B Kwiatkowski D.J Finlay G.A		0，，：	1
	2	Potential of Ne- palese entomopathogenic nematodes as biocontrol agents a- gainst Holotrichia longipennis Blanch, (Coleoptera Sear- abaeidae) 显示文摘	Hari B K C Govinda P T Hira K M etal	2011	Journal of Pest Science2011，84，4：	1
	3	Inhibition of Staphylococcus epidermidis biofilm formation by rabbit polyclonal antibodies against the SesC protein显示文摘	SHAHROOEI M HIRA V STIJLEMANS B	2009	Infect lmmun2009，77，9：	1
	4	Plasminogen activator inhibitor type 1(PAIl) and plateletgtycoprotein a (PG 显示文摘	Pegoraro RJ Hira B Rom L	2003	ActaOhstetGynecolSeand2003，82，31：	1
	5	Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein Ⅲ a( PGⅢa) polymorphisms in Black South Africans with preeclampsia 显示文摘	Pegoraro R J Hira B Rom L	2003	Acta Obstet Gynecol Scand2003，82，：	1
	6	Polymorphisms in various coagulation genes in black South African women with placental abruption显示文摘	Hira B Pegoraro RJ Rom L	2002	Br J obstet Gynaecol2002，109，：	1
	7	Spermicide Acceptability among Patients at a Sexually Transmitted Disease Clinic in Zambia显示文摘	Subhash K Hira Alan B Spruyt Paul J Feldblum	1995	American Journal of Pubic Health1995，85，8：	1
	8	Early congenital syphilis: clinico - radiology features in 202 patients 显示文摘	Hiras K Bhat G J Patel J B	1985	Sex Transm Dis1985，12，：	1
	9	Polymorphisms in various coagulation genes in black South African women with placental abruption显示文摘	Hira B Pegoraro RJ Rom L	2002	BJOG2002，109，5：	1
	10	Efficacy and safety outcomes with remdesivir in COVID-19 patients:A meta-analysis显示文摘BACKGROUND Remdesivir is a broad-spectrum antiviral drug having in vitro activity against severe acute respiratory syndrome coronavirus 2 and is currently being used on a compassionate basis outside of clinical trials.AIM To analyze the efficacy and safety of remdesivir compared with other interventions in coronavirus disease 2019(COVID-19)patients.METHODS We searched online databases to include randomized controlled trials evaluating the efficacy and safety of remdesivir compared with other interventions in COVID-19 patients.We summarized efficacy and safety data as risk ratios(RRs)with 95%confidence interval(CI)and used Mantel-Haenszel fixed or randomeffect models.We estimated the number needed to treat(NNT)to cause one additional outcome.We used the GRADE approach to assess the quality of the evidence for all outcome parameters.RESULTS We included four randomized controlled trials.We observed no significant difference in mortality(RR:0.83;95%CI:0.57–1.20;I2=59%)and rate of ventilation(RR:0.69;95%CI:0.41-1.18;I2=77%)between remdesivir-and placebo-treated patients.Remdesivir showed higher rates of clinical recovery than placebo(RR:1.10;95%CI:1.04–1.16;I2=0%;NNT:14.3).We observed no difference in overall adverse events between remdesivir-and placebo-treated patients(RR:1.05;95%CI:0.86–1.27;I2=77%).We observed less risk of serious adverse events(RR:0.75;95%CI:0.63–0.89;I2=0%)in remdesivir-than placebo-treated patients.The GRADE approach suggested moderate quality of evidence for all efficacy and safety outcomes.CONCLUSION We observed limited clinical benefit of remdesivir over placebo in the treatment of COVID-19.Our findings could be biased because of the small number of trials.	Tejas Kamleshbhai Patel Parvati B Patel Manish Barvaliya Vijayalaxmi Hira Lal Bhalla	2021	World Journal of Meta-Analysis2021，9，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费